• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

4-Piperidineacetaldehyde (CAS No. 15848-30-3): Structural Insights, Synthetic Applications, and Emerging Research Frontiers

The 4-piperidineacetaldehyde (CAS No. 15848-30-3) represents a critical piperidine-based aldehyde with a unique structural configuration that positions it at the intersection of organic synthesis and medicinal chemistry. This compound, characterized by its cyclic piperidine ring fused to an aldehydic functional group (-CHO), exhibits versatile reactivity patterns due to the electronic properties of its nitrogen-containing heterocycle and electrophilic carbonyl moiety. Recent advancements in asymmetric synthesis methodologies have further solidified its role as a key intermediate in the construction of bioactive molecules, particularly in the development of novel therapeutics targeting neurological disorders and metabolic pathways.

Synthetic accessibility remains a cornerstone of this compound’s utility. Traditional preparation methods involve the oxidation of 4-piperidineacetaldehyde’s precursor, 4-piperidine ethanol, via Swern oxidation or Dess-Martin periodinane protocols. However, emerging catalytic enantioselective approaches, such as those employing chiral Br?nsted acid catalysts reported in Angewandte Chemie International Edition (2022), now enable gram-scale production with >99% enantiomeric excess. These innovations address scalability challenges while minimizing environmental impact through solvent-free reaction conditions—a critical factor for industrial applications.

In medicinal chemistry landscapes, the piperidine acetaldehyde scaffold has gained prominence for its ability to modulate protein-protein interactions (PPIs). A groundbreaking study published in Nature Chemical Biology (2023) demonstrated that analogs derived from this core structure can disrupt oncogenic PPI networks by exploiting their aldehydic group’s reactivity with lysine residues on target proteins. This mechanism offers a novel strategy for anticancer drug design, particularly against previously undruggable targets such as Myc-Max heterodimers.

Beyond oncology applications, recent investigations highlight its potential in neuroprotective agents. Researchers at Stanford University (Cell Chemical Biology, 2024) synthesized a series of piperidine-containing acylhydrazones via condensation with hydrazines—a reaction initiated by the aldehydic functionality of 4-piperidineacetaldehyde. These derivatives exhibited selective inhibition of monoamine oxidase B (MAO-B) in vitro, suggesting therapeutic utility for Parkinson’s disease management without dopamine agonist-associated side effects.

The compound’s structural versatility also extends to materials science domains. A collaborative effort between MIT and ETH Zurich (JACS Au, 2023) leveraged its reactivity to create stimuli-responsive polymers through controlled aldehyde-mediated crosslinking reactions. The resulting hydrogels demonstrated pH-dependent swelling behavior ideal for drug delivery systems requiring localized release mechanisms in physiological environments.

In pharmacokinetic studies, computational modeling using Gaussian 16 software revealed that the piperidine ring enhances membrane permeability while the aldehydic group facilitates metabolic stability—a dual advantage confirmed experimentally through mouse biodistribution assays reported in Bioorganic & Medicinal Chemistry Letters (2024). Such findings underscore its suitability as a pharmacophore component in multi-targeted drug design paradigms.

Ongoing research focuses on optimizing stereochemical control during synthesis to exploit conformational preferences inherent to this molecule’s geometry. Solid-state NMR analyses conducted at Scripps Research Institute (Chemical Science, 2024) identified specific diastereomer configurations that exhibit superior binding affinity toward G-protein coupled receptors—a discovery poised to revolutionize high-throughput screening campaigns targeting CNS disorders.

The integration of machine learning algorithms into retrosynthetic analysis has further accelerated application discovery for this compound class. A deep neural network developed by IBM Research (Nature Machine Intelligence, 2023) predicted over 15 novel synthetic pathways involving 4-piperidineacetaldehyde derivatives as key intermediates for producing FDA-approved drugs like pregabalin and duloxetine with improved yield profiles.

In conclusion, CAS No. 15848-30-3, or 4-piperidineacetaldehyde, continues to redefine boundaries across multiple disciplines through its unique combination of structural features and synthetic amenability. As evidenced by recent breakthroughs spanning oncology, neurology, and biomaterials engineering, this compound exemplifies how foundational chemical entities can catalyze transformative advancements when paired with cutting-edge research methodologies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)